Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Metaxon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.63 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.59 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | PPARD | Q03181 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metaxon SCHEMBL117877 | 0.98 | TDP1 (0.70) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL27765431 | 0.97 | TDP1 (0.68) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL18221951 | 0.97 | TDP1 (0.68) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL27616565 | 0.97 | TDP1 (0.68) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL28800416 | 0.97 | TDP1 (0.68) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL27542877 | 0.94 | TDP1 (0.64) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL4880562 | 0.94 | TDP1 (0.75) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL9718318 | 0.92 | TDP1 (0.82) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL28681554 | 0.92 | TDP1 (0.62) | TDP1NPSR1TSHRPPARDPPARG | |
| Metaxon SCHEMBL8762755 | 0.91 | TDP1 (0.60) | TDP1NPSR1TSHRPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| US-10633349-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9969700-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-09-29 | — | — | US | disclosed |
| EP-1893615-A1 | PYRROLOBENZODIAZEPINE PYRIDINE CARBOXAMIDES AND DERIVATIVES AS FOLLICLE-STIMULATING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1879897-A1 | PYRROLOBENZODIAZEPINES AND HETEROARYL, ARYL AND CYCLOALKYLAMINO KETONE DERIVATIVES AS FOLLICLE STIMULATING HORMONE RECEPTOR -(FISH-R) ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006135687-A1 | PYRROLOBENZODIAZEPINE PYRIDINE CARBOXAMIDES AND DERIVATIVES AS FOLLICLE-STIMULATING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006124523-A1 | PYRROLOBENZODIAZEPINES AND HETEROARYL, ARYL AND CYCLOALKYLAMINO KETONE DERIVATIVES AS FOLLICLE STIMULATING HORMONE RECEPTOR -(FISH-R) ANTAGONISTS | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258644-A1 | Pyrrolobenzodiazepines and heteroaryl, aryl and cycloalkylamino ketone derivatives as follicle stimulating hormone receptor (FSH-R) antagonists | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-09-07 | — | — | US | disclosed |
| CN-1044818-A | HERBICIDAL OXABICYCLONONANE ETHERS | DU PONT (US) | 1990-08-22 | — | — | CN | disclosed |
| CN-1035415-A | The herbicidal composition of post-emergent application in corn | NITROKEMIA IPARTELEPEK (HU) | 1989-09-13 | — | — | CN | disclosed |
| US-4067726-A | 3-Ureido phenylacetamide herbicides | BAYER AKTIENGESELLSCHAFT (DT) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258644-A1 | Pyrrolobenzodiazepines and heteroaryl, aryl and cycloalkylamino ketone derivatives as follicle stimulating hormone receptor (FSH-R) antagonists | FSHR, GNRHR, PRLHR | PPARG 283/4885GAA 4285/4885KCNH2 490/4885 |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | PPARG 1187/4885GAA 4772/4885KCNH2 131/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | PPARG 972/4885GAA 4802/4885KCNH2 93/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | PPARG 1187/4885GAA 4772/4885KCNH2 131/4885 |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | PPARG 1217/4885GAA 4777/4885KCNH2 139/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | PPARG 1187/4885GAA 4772/4885KCNH2 131/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | PPARG 1187/4885GAA 4772/4885KCNH2 131/4885 |
| US-10633349-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | PPARG 1187/4885GAA 4772/4885KCNH2 131/4885 |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | PPARG 1187/4885GAA 4772/4885KCNH2 131/4885 |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | FSHR, GNRHR, PRLHR | PPARG 187/4885GAA 4783/4885KCNH2 883/4885 |
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | FSHR, GNRHR, LHCGR | PPARG 170/4885GAA 4640/4885KCNH2 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.